Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era

Overview

Journal J Pers Med

Date 2021 Jun 2

PMID 34063507

Citations 11

Authors

Raksha Jain

Jennifer L Taylor-Cousar

Affiliations

Soon will be listed here.

Abstract

Cystic fibrosis (CF) is an autosomal recessive genetic disorder impacting approximately 80,000 people of all races and ethnicities world-wide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which encodes a protein of the same name. Protein dysfunction results in abnormal chloride and bicarbonate transport in mucus membranes, including those in the respiratory, gastrointestinal and reproductive tracts. Abnormal anion transport causes viscous secretions at the site of involvement. The majority of people with CF succumb to respiratory failure following recurrent cycles of infection and inflammation in the airways. Historically, providers treated the signs and symptoms of CF, but since 2012, have been able to impact the basic defect for the subset of people with CF who have mutations that respond to the new class of drugs, CFTR protein modulators. With the improved health and longevity afforded by CFTR modulators, more women are interested in parenthood and are becoming pregnant. Furthermore, this class of drugs likely increases fertility in women with CF. However, the safety of CFTR modulators in pregnancy and lactation is only beginning to be established. We summarize available data on the impact of CFTR modulators on fertility, pregnancy and lactation in women with CF.

Citing Articles

Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis.

Gross J, Jones M, Buige A, Prevots D, Kasperbauer S Ther Adv Respir Dis. 2025; 19:17534666251323181.

PMID: 40071337 PMC: 11898043. DOI: 10.1177/17534666251323181.

Challenges of Preimplantation Genetic Counselling in the Context of Cystic Fibrosis and Other CFTR-Related Disorders: A Monocentric Experience in a Cohort of 92 Couples.

Sorrentino U, Menegazzo M, Gabbiato I, Calosci D, Zambon C, Zuccarello D Genes (Basel). 2024; 15(7).

PMID: 39062716 PMC: 11275312. DOI: 10.3390/genes15070937.

Ocular development after highly effective modulator treatment early in life.

Zhu Y, Li D, Reyes-Ortega F, Chinnery H, Schneider-Futschik E Front Pharmacol. 2023; 14:1265138.

PMID: 37795027 PMC: 10547496. DOI: 10.3389/fphar.2023.1265138.

Unplanned pregnancies following the introduction of elexacaftor/tezacaftor/ivacaftor therapy in women with cystic fibrosis.

Dacco V, Alicandro G, Trespidi L, Gramegna A, Blasi F Arch Gynecol Obstet. 2023; 308(5):1657-1659.

PMID: 37517074 DOI: 10.1007/s00404-023-07153-y.

Reproductive Counseling and Care in Cystic Fibrosis: A Multidisciplinary Approach for a New Therapeutic Era.

McGlynn J, DeCelie-Germana J, Kier C, Langfelder-Schwind E Life (Basel). 2023; 13(7).

PMID: 37511919 PMC: 10381247. DOI: 10.3390/life13071545.

References

Cohen-Cymberknoh M, Gindi Reiss B, Reiter J, Lechtzin N, Melo J, Perez G . Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. J Cyst Fibros. 2020; 20(3):388-394. DOI: 10.1016/j.jcf.2020.09.002. View

Stead R, Hodson M, Batten J, Adams J, Jacobs H . Amenorrhoea in cystic fibrosis. Clin Endocrinol (Oxf). 1987; 26(2):187-95. DOI: 10.1111/j.1365-2265.1987.tb00776.x. View

Fortner C, Seguin J, Kay D . Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021; 20(5):835-836. DOI: 10.1016/j.jcf.2021.03.018. View

Edenborough F . Women with cystic fibrosis and their potential for reproduction. Thorax. 2001; 56(8):649-55. PMC: 1746112. DOI: 10.1136/thorax.56.8.649. View

Taylor-Cousar J, Munck A, McKone E, van der Ent C, Moeller A, Simard C . Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017; 377(21):2013-2023. DOI: 10.1056/NEJMoa1709846. View

Ramsey B, Davies J, McElvaney N, Tullis E, Bell S, Drevinek P . A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-72. PMC: 3230303. DOI: 10.1056/NEJMoa1105185. View

Korzeniewska A, Grzelewski T, Jerzynska J, Majak P, Soloniewicz A, Stelmach W . Sexual and reproductive health knowledge in cystic fibrosis female patients and their parents. J Sex Med. 2009; 6(3):770-6. DOI: 10.1111/j.1743-6109.2008.01049.x. View

GAN K, Geus W, Bakker W, Lamers C, Heijerman H . Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years. Thorax. 1995; 50(12):1301-4. PMC: 1021355. DOI: 10.1136/thx.50.12.1301. View

Patel E, Swamy G, Heine R, Kuller J, James A, Grotegut C . Medical and obstetric complications among pregnant women with cystic fibrosis. Am J Obstet Gynecol. 2014; 212(1):98.e1-9. DOI: 10.1016/j.ajog.2014.07.018. View

10.

Chen H, Guo J, Lu Y, Ding G, Yu M, Tsang L . Impaired CFTR-dependent amplification of FSH-stimulated estrogen production in cystic fibrosis and PCOS. J Clin Endocrinol Metab. 2011; 97(3):923-32. DOI: 10.1210/jc.2011-1363. View

11.

Schram C, Stephenson A, Hannam T, Tullis E . Cystic fibrosis (cf) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (amh) in young women. J Cyst Fibros. 2014; 14(3):398-402. DOI: 10.1016/j.jcf.2014.09.008. View

12.

McCloskey M, REDMOND A, Hill A, Elborn J . Clinical features associated with a delayed diagnosis of cystic fibrosis. Respiration. 2000; 67(4):402-7. DOI: 10.1159/000029538. View

13.

Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D . Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019; 381(19):1809-1819. PMC: 7282384. DOI: 10.1056/NEJMoa1908639. View

14.

Neinstein L, Stewart D, Wang C, Johnson I . Menstrual dysfunction in cystic fibrosis. J Adolesc Health Care. 1983; 4(3):153-7. DOI: 10.1016/s0197-0070(83)80367-2. View

15.

Edenborough F, Borgo G, Knoop C, Lannefors L, Mackenzie W, Madge S . Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros. 2007; 7 Suppl 1:S2-32. DOI: 10.1016/j.jcf.2007.10.001. View

16.

Jones G, Walshaw M . Potential impact on fertility of new systemic therapies for cystic fibrosis. Paediatr Respir Rev. 2015; 16 Suppl 1:25-7. DOI: 10.1016/j.prrv.2015.07.013. View

17.

Vekaria S, Popowicz N, White S, Mulrennan S . To be or not to be on CFTR modulators during pregnancy: Risks to be considered. J Cyst Fibros. 2019; 19(2):e7-e8. DOI: 10.1016/j.jcf.2019.12.004. View

18.

Munster E, Letzel S, Passet-Wittig J, Schneider N, Schuhrke B, Seufert R . Who is the gate keeper for treatment in a fertility clinic in Germany? -baseline results of a prospective cohort study (PinK study). BMC Pregnancy Childbirth. 2018; 18(1):62. PMC: 5839010. DOI: 10.1186/s12884-018-1690-8. View

19.

Wainwright C, Elborn J, Ramsey B, Marigowda G, Huang X, Cipolli M . Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015; 373(3):220-31. PMC: 4764353. DOI: 10.1056/NEJMoa1409547. View

20.

Trimble A, McKinzie C, Terrell M, Stringer E, Esther Jr C . Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros. 2018; 17(6):779-782. PMC: 6354249. DOI: 10.1016/j.jcf.2018.05.009. View